ReviewCancer management and research2025
Treatment and Outcomes of Primary Tracheal Adenoid Cystic Carcinoma: A Systematic Review.
Review in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Adenoid cystic carcinoma of the trachea: an uncommon presentation of a rare malignancy.Journal of surgical case reports · 2026Article
- Cryobiopsy in the Diagnosis of Pulmonary Vein Stenosis After Catheter Ablation of Atrial Fibrillation: A Case Report.Respirology case reports · 2026Article
- Efficacy and survival of photodynamic treatment for tracheal adenoid cystic carcinoma: a two-center retrospective analysis.Journal of thoracic disease · 2025Article
- Outcomes and prognostic insights in primary tracheal cancer: a multicenter retrospective study.Translational lung cancer research · 2025Article
- Single-cell sequencing atlas construction for tracheobronchial adenoid cystic carcinoma.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary tracheal adenoid cystic carcinoma (TACC) is a rare malignant tumor. This systematic review describes the treatment strategies and oncological outcomes in patients with TACC. Full-text English manuscripts published from January 1st 1960, to December 31th 2023, were included. Data on demographics, treatment, and outcomes were also collected. A pooled analysis of 5-year overall survival (OS) was performed. Nineteen articles and 1488 patients met the inclusion criteria. The first-choice treatment strategy was surgery (74.5%), whereas adjuvant radiotherapy was administered to 56.7% of the patients. The follow-up range was 6-390 months. A total of 552 deaths were recorded, 98.7% of which were cancer related. The 5-year OS rate ranged from 28.6% to 100.0%; in the pooled analysis, it was 65% (range, 32%-96%). Surgery remains the mainstay of treatment for TACC. Adjuvant radiotherapy is commonly administered to patients with positive margins, and survival estimates are good overall but heterogeneous.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.